Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia

Blood

Volumn 99, Issue 7, 2002, Pages 2615-2616

  Bernard, Frédéric ^a,b   Thomas, Caroline ^a,b   Emile, Jean François ^a,b   Hercus, Timothy ^a,b   Cassinat, Bruno ^a,b   Chomienne, Christine ^a,b   Donadieu, Jean ^a,b  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; PROTEIN E21R; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BONE MARROW CULTURE; CASE REPORT; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MALE; MYELOMONOCYTIC LEUKEMIA; PRIORITY JOURNAL; RECEPTOR BINDING; SCHOOL CHILD; SIDE EFFECT; STEM CELL;

EID: 0036529829     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.7.2615     Document Type: Article

References (6)

1. Juvenile myelomonocytic leukemia
2. Treatment of juvenile chronic myelomonocytic leukemia by allogeneic bone marrow transplantation
3. Specific human granulocyte-macrophage colonlystimulating factor antagonists
4. Residue 21 of human granulocyte-macrophage colonystimulating factor is critical for biological activity and for high but not low affinity binding
5. Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulating factor analogue E21 R
6. Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice